Literature DB >> 10668344

[Ticlopidine-associated thrombotic thrombocytopenic purpura (Morbus Moschcowitz)].

J Carlsson1, S Miketic, R Bätge, P Riedel, G Rahlf, U Tebbe.   

Abstract

ANAMNESIS AND CLINICAL
FINDINGS: A 75-year-old woman with a history of recurrent ischemic cerebral events was admitted with acute unspecific neurological symptoms and fever. EXAMINATION: Intracerebral hemorrhage due to hypertension and antithrombotic therapy with ticlopidine was ruled out with cranial computed tomography. Laboratory findings on admission included thrombocytopenia (12/nl), renal insufficiency (serum creatinine 1.6 mg/dl) and LDH elevation (1,218 U/l). The hemoglobin on admission was normal. THERAPY AND CLINICAL COURSE: In the presence of rapidly declining hemoglobin values and fragmentation of red cells thrombotic-thrombocytopenic purpura (TTP) was diagnosed and the patient received fresh frozen plasma. Shortly after the plasma infusion the patient's condition deteriorated rapidly showing clinical signs of an allergic shock. In the sequel of 24 to 48 hours the patient developed renal failure, severe anemia and the thrombocyte count fell to 5/nl. The patient was mechanically ventilated during the next 48 hours and needed intravenous catecholamines. Even after restoration of spontaneous respiration and cessation of pharmacological sedation the patient remained comatose. Cranial computed tomography on the fourth day after admission showed multiple infarction syndrome. The patient died on the ninth day after admission in status epilepticus which could not be stopped with pharmacological means.
CONCLUSIONS: The combination of neurological symptoms, thrombocytopenia, fever, renal failure and hemolytic anemia in a patient taking ticlopidine points to a diagnosis of TTP. The high mortality of TTP can probably only be reduced by early plasmapheresis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10668344     DOI: 10.1007/bf03044980

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  22 in total

1.  TTP--desperation, empiricism, progress.

Authors:  J L Moake
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

2.  Thrombotic thrombocytopenic purpura after stenting and ticlopidine.

Authors:  C L Bennett; J E Kiss; P D Weinberg; A J Pinevich; D Green; H C Kwaan; M D Feldman
Journal:  Lancet       Date:  1998-09-26       Impact factor: 79.321

3.  Blood dycrasias and hematologic reactions in ticlopidine users.

Authors:  D K Wysowksi; J Bacsanyi
Journal:  JAMA       Date:  1996-09-25       Impact factor: 56.272

4.  Aplastic anemia associated with ticlopidine.

Authors:  C M Shapiro; D Walk
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP.

Authors:  E Bobbio-Pallavicini; L Gugliotta; R Centurioni; C Porta; N Vianelli; A Billio; F Tacconi; E Ascari
Journal:  Haematologica       Date:  1997 Jul-Aug       Impact factor: 9.941

6.  High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients.

Authors:  M Rose; A Eldor
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

7.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

8.  Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report.

Authors:  R Capra; N Marcianò; F Fieni; M Capucci; P Ferremi; A Orlandini
Journal:  Acta Neurol Belg       Date:  1992       Impact factor: 2.396

9.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

10.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

Authors:  W K Hass; J D Easton; H P Adams; W Pryse-Phillips; B A Molony; S Anderson; B Kamm
Journal:  N Engl J Med       Date:  1989-08-24       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.